GlassScriptPhysician profile
Arthur Gudeon
NPI 1649340753
$2,602.07
in general payments reported to CMS, 2019-2025
13 companies · $805 in 2025
The $805 reported for 2025 was more than what 76% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2021: $130 · 2022: $242 · 2023: $381 · 2024: $528 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $427.31 | 2019-2025 | Collagenase Santyl, Oasis |
| Abbott Laboratories | $411.24 | 2019-2022 | |
| Kerecis Limited | $378.25 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Lifenet Health | $246.83 | 2023-2025 | Theragenesis Wound Matrix |
| Bioventus LLC | $209.42 | 2025 | Exogen Ultrasound Bone Healing System |
| Orthofix Medical, INC. | $170.43 | 2025 | Physio-Stim |
| Cardiovascular Systems INC. | $130.00 | 2021 | |
| Paratek Pharmaceuticals, INC. | $121.24 | 2025 | Nuzyra |
| Averitas Pharma INC. | $111.05 | 2023 | Qutenza |
| Grt US Holding, INC. | $104.09 | 2022 | |
| Organogenesis INC. | $99.80 | 2024 | Affinity, Novachor, Nushield |
| Convatec INC. | $96.66 | 2024 | |
| Solventum Corporation | $95.75 | 2025 | Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Gudeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.